公开(公告)号：US20220289803A1

公开(公告)日：2022-09-15

申请号：US17664589

申请日：2022-05-23

Applicant: Genentech, Inc.

Inventor： Yichin LIU ,  Christine Carine MOUSSION ,  Travis William BAINBRIDGE ,  Iraj HOSSEINI ,  Gregory Alan LAZAR ,  Sivan COHEN ,  Christopher Charles KEMBALL ,  Jill M. SCHARTNER

IPC: C07K14/475 ,  A61K38/18 ,  A61K31/713 ,  A61K39/395 ,  C07K16/28

Abstract: The invention provides an effectoriess immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.

公开(公告)号：US20240132613A1

公开(公告)日：2024-04-25

申请号：US18531287

申请日：2023-12-06

Applicant: Genentech, Inc.

Inventor： Yu-Waye CHU ,  Iraj HOSSEINI ,  Saroja RAMANUJAN ,  Kapil GADKAR ,  Chi-Chung LI

IPC: C07K16/28 ,  A61K31/573 ,  A61K39/395

CPC classification number: C07K16/2887 ,  A61K31/573 ,  A61K39/3955 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2866 ,  A61K2039/507

Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

公开(公告)号：US20180134798A1

公开(公告)日：2018-05-17

申请号：US15813657

申请日：2017-11-15

Applicant: Genentech, Inc.

Inventor： Yu-Waye CHU ,  Iraj HOSSEINI ,  Saroja RAMANUJAN ,  Kapil GADKAR ,  Chi-Chung LI

IPC: C07K16/28 ,  A61K31/573 ,  A61K39/395

CPC classification number: C07K16/2887 ,  A61K31/573 ,  A61K39/3955 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41

Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

公开(公告)号：US20220153858A1

公开(公告)日：2022-05-19

申请号：US17516794

申请日：2021-11-02

Applicant: Genentech, Inc.

Inventor： Chi-Chung LI ,  Carol Elaine O'HEAR ,  Hong WANG ,  Brendan Christian BENDER ,  Iraj HOSSEINI

IPC: C07K16/28 ,  A61K31/573 ,  A61K39/395 ,  A61P35/00 ,  A61P35/02

Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of an anti-CD20/anti-CD3 bispecific antibody.